Immunotherapy resistance: the answers lie ahead - not in front - of us
Miles C Andrews1, Jennifer A Wargo1,2
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX 77030 USA.
Abstract:
Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manuscript by Zaretsky and colleagues, mutational events were identified that effectively crippled ongoing immunotherapy responses in patients treated with anti-PD-1 therapy. These results are discussed in the light of other recent and ongoing research efforts exploring both mutational and non-mutational resistance mechanisms, highlighting the critical translational importance of longitudinal tumor sampling.
Insights
Checkpoint blockade immunotherapy can be hindered by specific mutations that stop anti-PD-1 therapy responses. Understanding these resistance mechanisms is vital for improving cancer treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Checkpoint blockade immunotherapy, particularly anti-PD-1 therapy, shows promise in cancer treatment.
- Investigating mechanisms of innate and adaptive resistance is crucial for enhancing therapeutic efficacy.
Discussion:
- Zaretsky and colleagues identified specific mutational events that compromise ongoing anti-PD-1 therapy responses.
- These findings contribute to a broader understanding of acquired resistance to cancer immunotherapies.
Key Insights:
- Acquired resistance to anti-PD-1 therapy can be driven by specific genetic alterations within tumors.
- Identifying these resistance mechanisms is critical for predicting patient response and guiding treatment strategies.
Outlook:
- Further research into both mutational and non-mutational resistance mechanisms is warranted.
- Longitudinal tumor sampling is highlighted as a critical translational approach for monitoring resistance evolution and optimizing immunotherapy.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
Tumor Immunotherapy
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
